As of November 14, 2026, CorMedix Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 8, 2026 (Form 8-K, January 8, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like CorMedix Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
CorMedix Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-08. Every row below is cited to the filing it comes from, and this page adds each new change as CorMedix Inc. files it.
Also on the record for CorMedix Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 12, 2026 | Stake report, Schedule 13G/A, by SHAIBATALHAMD AYMEN ABDALKADER | 5.9% of the class | 5%+ stakes | Source |
| June 12, 2026 | Stake report, Schedule 13G/A, by SHAIBATALHAMD AYMEN ABDALKADER | 5.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 7.94% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 2, 2026 | Stake report, Schedule 13G/A, by SHAIBATALHAMD AYMEN ABDALKADER | 5.8% of the class | 5%+ stakes | Source |
| December 1, 2025 | Stake report, Schedule 13G, by Deep Track Capital, LP | 6.29% of the class | 5%+ stakes | Source |
| August 8, 2025 | Stake report, Schedule 13G/A, by SHAIBATALHAMD AYMEN ABDALKADER | 6.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs CorMedix Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on CorMedix Inc. and the records around it.
CorMedix Inc. elsewhere on the record
Companies that share a holder
- Deep Track Capital, LP also filed stake reports on 60 other companies: Mentari Therapeutics, Inc. (Nov 2026), Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026)
- The Vanguard Group also filed stake reports on 2385 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch CorMedix Inc.
Get an email when CorMedix Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CorMedix Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on CorMedix Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CorMedix Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-01-08 | Reported | not named in the filing | 8-K, 2026-01-08 |
New leaders reset buying decisions — get the Full Report on CorMedix Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at CorMedix Inc., with the record behind each one.
Find candidates like senior executive at CorMedix Inc.Every change, in the filing's words
Reported
Mr. Todisco's appointment as Chairman of the Board, effective January 8, 2026, was approved by the Board on January 5, 2026.
- On January 5, 2026, the Company entered into an amended and restated executive employment agreement (the "A&R Employment Agreement") with Joseph Todisco, the Company's Chief Executive Officer.
- Pursuant to the A&R Employment Agreement, Mr. Todisco will continue to serve as the Company's Chief Executive Officer and will also serve as the Chairman of the Company's board of directors (the "Board").
- Pursuant to the A&R Employment Agreement, Mr. Todisco's annual base salary increased from $665,000 to $750,000 effective as of January 1, 2026 and his target annual bonus opportunity increased from 65% to 75% of his base salary, beginning with the Company's 2026 fiscal year, with the actual amount of any annual bonus to be determined based on achievement of Company and individual objectives set by the Board (or its compensation committee) after consultation with Mr. Todisco.
- Mr. Todisco will also be eligible to receive grants pursuant to the Company's 2019 Omnibus Stock Incentive Plan or any successor thereto (the "Equity Plan") from time to time as determined by the Board (or its compensation committee).
- The A&R Employment Agreement also contains customary confidentiality and non-disparagement covenants and non-competition and non-solicitation of employees and customers covenants that apply during employment and for a period of 18 months following any termination of employment.
Tools for this story
Each opens in a new tab, filled in for CorMedix Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
